Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Follow-Up Questions
What is Indaptus Therapeutics Inc (INDP)'s P/E Ratio?
The P/E ratio of Indaptus Therapeutics Inc is N/A
Who is the CEO of Indaptus Therapeutics Inc?
Mr. Jeffrey Meckler is the Chief Executive Officer of Indaptus Therapeutics Inc, joining the firm since 2021.
What is the price performance of INDP stock?
The current price of INDP is 2.54, it has decreased 1.12% in the last trading day.
What are the primary business themes or industries for Indaptus Therapeutics Inc?
Indaptus Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Indaptus Therapeutics Inc market cap?
Indaptus Therapeutics Inc's current market cap is $2.8
Is Indaptus Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Indaptus Therapeutics Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
